Launch of Scopus AI to Help Researchers Navigate the World of Research

Elsevier, a global leader in scientific information and data analytics, today launches Scopus AI – a generative AI product to help researchers and research institutions get fast and accurate summaries and research insights that support collaboration and societal impact.

Scopus AI is based on Scopus’ trusted content from over 27,000 academic journals, from more than 7,000 publishers worldwide, with over 1.8 billion citations, and includes over 17 million author profiles. Scopus content is vetted by an independent board of world-renowned scientists and librarians who represent the major scientific disciplines.

Since the alpha launch in August 2023, thousands of researchers across the world have tested Scopus AI. Their feedback has reinforced that, as generative AI evolves, researchers want trustworthy, cited research that is relevant and highly personalized to their needs.

Feedback from the research community has led to Scopus AI offering the following powerful features:

• Expanded and Enhanced Summaries that provide researchers with fast overviews of key topics that they can dig deeper into, sometimes even highlighting gaps in literature. Scopus AI’s advanced engineering minimizes the risk of 'hallucinations' — or false AI-generated information — by using the trustworthy and verified knowledge from the world’s largest database of curated scientific literature.

• Foundational and Influential Papers that enable researchers to rapidly pinpoint seminal works, navigating academic progress and impact with precision and ease.

• Academic Expert Search identifies leading experts in their fields and provides explanations of their expertise relevant to the user’s query, helping save time.

• Enhanced breadth of research, covering ten years of Scopus content to support well-rounded perspective on topics of interest, and improved design to enhance the user experience.

Maxim Khan, SVP of Analytics Products and Data Platform, Elsevier, said: “I want to thank the students, researchers and customers who played a critical role in Scopus AI’s development. Scopus AI is built on trusted knowledge and data that will help accelerate understanding of new research topics, provide deeper research insights, identify relevant research and experts in a particular field, all with the aim of paving the way for academic success. We will continue to work with the community as we constantly enhance Scopus AI.”

Elisenda Aguilera, a researcher at the Pompeu Fabra University in Spain who has taken part in Scopus AI testing and produced a preprint 新しいタブ／ウィンドウで開く on her learnings, said: “The Scopus AI interface is intuitive and easy to use, it allows the researcher to obtain an overview of a problem, as well as identify authors and approaches, in a more agile search session than conventional search. It is a valuable tool for literature reviews, construction of theoretical frameworks and verification of relationships between variables, among other applications that are actually impossible to delimit.”

Scopus AI is now available worldwide for Scopus customers to purchase. You can learn more about Scopus AI, view a short demo and register your interest here.

For more than a decade, Elsevier has been using AI and machine learning technologies in its products combined with its unparalleled peer-reviewed content, extensive data sets and sophisticated analytics to help researchers, clinicians, students and educators achieve their goals. Customer experience, data privacy and integrity, and responsible AI are at the heart of Elsevier’s product development, in line with our Responsible AI Principles and Privacy Principles.

エルゼビアについて エルゼビアは、科学情報と分析を牽引するグローバル企業として、研究者や医療従事者が社会の利益のために科学を進歩させ、医療成果を向上させることを支援しています。我々は信頼できるエビデンスベースのコンテンツと高度なAI対応デジタルテクノロジーに基づくソリューションにより、インサイトと重要な意思決定を促進することでこれを実現しています。

エルゼビアは、140 年以上にわたり研究および医療コミュニティの活動を支援してきました。全世界で 2,500 人以上の技術者を含む 9,500 人の従業員がおり、重要な職務における研究者や、図書館員、アカデミックリーダー、資金提供者、政府機関、R&D 関連企業、医師、看護師、将来の医療従事者や教育者を支援することに従事してきました。2,900 誌以上の科学ジャーナルと代表的な参考文献には、Cell Press、The Lancet、Gray's Anatomy など、各分野の主要なタイトルを含みます。 エルゼビア・ファウンデーション 新しいタブ／ウィンドウで開くと共に、開発途上国および世界中の科学、研究、医療分野におけるインクルージョン＆ダイバーシティ 新しいタブ／ウィンドウで開くを推進するため、支援コミュニティと連携して活動しています。 エルゼビアは、プロフェッショナルおよびビジネス顧客向けの情報に基づく分析および意思決定ツールのグローバルプロバイダーである RELX 新しいタブ／ウィンドウで開くグループの一部です。業務内容やデジタルソリューション、コンテンツ詳細については、 www.elsevier.com/ja-jpをご参照ください。